Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
Crossref DOI link: https://doi.org/10.1007/s00280-016-3218-0
Published Online: 2017-01-10
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Quartino, Angelica L.
Li, Hanbin
Jin, Jin Y.
Wada, D. Russell
Benyunes, Mark C.
McNally, Virginia
Viganò, Lucia
Nijem, Ihsan
Lum, Bert L.
Garg, Amit
Funding for this research was provided by:
F. Hoffmann-La Roche
License valid from 2017-01-10